Formulation of fast-opening oral tablet of amlodipine 5 mg and investigation of its physicochemical properties

Number of pages: 115 File Format: word File Code: 32037
Year: 2012 University Degree: Master's degree Category: Paramedical
  • Part of the Content
  • Contents & Resources
  • Summary of Formulation of fast-opening oral tablet of amlodipine 5 mg and investigation of its physicochemical properties

    Dissertation

    To receive the degree of Doctor of Pharmacy

    Persian Summary

    Orally disintegrating tablets are solid pharmaceutical forms that open in the oral cavity in less than 1 minute without leaving a residue. The purpose of this research is to prepare and evaluate fast-opening oral tablets of amlodipine mg5, which is a long-acting blocker of calcium channels used in the treatment of chronic stable angina, vasospastic angina, and hypertension. In this study, quick-release oral tablets of amlodipine were prepared by direct compression method. In this thesis, the new auxiliary material F-Melt is used. Also, cross-carmellose sodium and sodium starch glycolate openers were used with different percentages. After conducting pre-formulation studies on the powder, we performed physicochemical control tests including diameter, thickness, weight uniformity, erosion, hardness, opening time, as well as tests to determine the amount of the effective substance and dissolution test on all formulations. Finally, the superior formulation was selected for taste evaluation. At this stage, we used different sweeteners and flavorings with different percentages, and finally the formulation with the highest taste acceptance was identified as the superior formulation. Due to the lack of this pharmaceutical form in the world market, it is hoped that we can mass produce this product in one of the domestic factories.

    Key words: superdisintegrants, direct condensation, F-Melt, Avicel, magnesium stearate, mannitol, Karr index and Hasner coefficient.

    . Necessity and importance of the topic

    Amlodipine is a drug from the family of long-acting calcium channel blockers, which is used in the treatment of chronic stable angina, vasospastic angina, and hypertension. The way to take this medicine is orally. The oral route is easy to use. Among the oral pharmaceutical forms are tablets, which are among the most widely used pharmaceutical forms due to their ease of manufacture and good stability, as well as lower cost and easier transportation. More than 50% of the pharmaceutical forms of the market are pills. For this reason, the use of this medicinal form has a high priority. But this form of medicine also has some drawbacks. The first drawback to this form of medicine is the problem of swallowing. Some people, including children and the elderly, do not have a high swallowing ability. Also, people suffering from schizophrenia keep the pill in their mouth and do not swallow it. Also, the pill must go through several stages after swallowing. including opening, dissolving and absorption. Opening and turning into a solution form is a time-consuming process that delays the onset of the drug's effect, and from this point of view, liquid pharmaceutical forms are preferable to solid pharmaceutical forms. Due to the fact that liquid pharmaceutical forms are bulky, their use is relatively less than solid pharmaceutical forms. In recent years, the use of fast-opening oral tablets is more than in the past, these tablets have the ability to open and turn into granules after being placed in the mouth and contact with saliva, and in some cases dissolve completely. These tablets, while having the advantages of a solid form of medicine, can quickly dissolve into a suspension or solution after being placed in the mouth, and then have the advantages of liquid forms of medicine and the possibility of faster absorption of the drug and faster entry into the bloodstream and ease of swallowing for that level. Considering the swallowing problems in the elderly, the use of this medicinal form for amlodipine tablets is considered an advantage. Therefore, the aim of this thesis is to prepare amlodipine mg5 quick-release oral tablet that can release the drug quickly and also has the most suitable formulation.

    1-2. Statement of the problem

    The most common way of taking medicine is oral. The oral route is very easy to use and due to the large area of ??the digestive tract, it provides the possibility of wide absorption. Among the oral pharmaceutical forms are tablets, which are among the most widely used pharmaceutical forms due to their ease of manufacture and good stability, as well as lower cost and easier transportation. Pills make up more than 50% of the pharmaceutical forms in the market.For this reason, the use of this medicinal form has a high priority. One of the problems of the pill is that it causes problems for people who have swallowing problems (children and the elderly) and after swallowing the pill must go through the stages of opening, dissolution and absorption. The stage of opening and converting to a soluble form is a time-consuming process that causes a delay in the onset of the therapeutic effect, and from this point of view, liquid pharmaceutical forms are preferable to solid pharmaceutical forms. Due to the fact that liquid pharmaceutical forms are bulky, their use is relatively less than solid pharmaceutical forms, and in recent years, the use of fast-opening oral tablets has increased. These tablets have the ability to open and turn into granules after being placed in the mouth and contact with saliva, and in some cases dissolve completely, and for this reason, the digestive side effects of these medicinal systems are few (1, 2, 3). Their mechanism of action in high blood pressure (and to some extent angina) is to inhibit the entry of calcium into the arterial smooth muscle cells (3, 4).

    The design of pregastric absorption systems improves the bioavailability and reduces the drug dose, and by reducing the side effects of the drug, they improve the clinical performance of the drug.

    1-3. Objectives

    Main objectives

    Preparation of the formulation of quick-release oral tablet of amlodipine, subsequently investigating the physicochemical properties of the prepared formulations in order to achieve the final formulation, which has the desired physicochemical properties and good stability.

    Objectives Sub

    Investigation of the physicochemical properties of amlodipine

    Preparation and various formulations of the drug amlodipine in order to obtain fast-opening tablets

    Perform various physicochemical tests to evaluate the prepared formulations

    Checking the taste of selected formulations in order to achieve a formulation with the desired taste

    Abstract

    Orally Disintegrating Tablets (ODTs) are solid dosage forms that disintegrate in the oral cavity under 1 minute leaving no residue. Amlodipine is a calcium channel blocker used in the treatment of angina and hypertension. In the present work, ODTs of Amlodipine were prepared by the direct compression method. Prior to the start of formulation studies, preliminary studies were conducted on the Amlodipine powder in order to justify its suitability for use in this study.

    Results approved the suitability of powder for use. Next, formulation studies were carried out using different superdisintegrants (F-Melt, crosscarmelose sodium, crospovidone and sodium starch glycolate) with different fillers (Avicel, lactose, starch and calcium carbonate) and different lubricants (Mg Stearate, SLS and sodium benzoate).

    Formulations prepared underwent different physicochemical tests. including weight variation, hardness, diameter, thickness, friability, drug content, disintegration and dissolution time.

    Results showed that among different fillers, Avicel is the best. F-Melt was found to be the best providing a disintegration time of 8 seconds. The best lubricant was Mg Stearate.

    Different flavoring agents were added and the mixture of menthol and sodium saccharin was found to be the best.

    Finally formulation D21 containing Amlodipine, Avicel, F-Melt, Mg Stearate, Menthol, sodium saccharin and mannitol was chosen as the most desirable formulation and underwent complimentary studies including dissolution and assay.

  • Contents & References of Formulation of fast-opening oral tablet of amlodipine 5 mg and investigation of its physicochemical properties

    List:

    Page

    Persian Summary.. 1

     

    Chapter One: Overview

    1-1. The necessity and importance of the subject. 3

    1-2. Statement of the problem .. 4

    1-3. Objectives.. 4

    Chapter Two: Review of the literature and studies of others in this field

    Part One: Quick-release tablets

    1-2. tablet.. 8

    2-1-1. Benefits of pills.. 9

    2-1-2. Disadvantages of pills.. 10

    2-1-3. Types of pills.. 10

    2-1-3-1. Oral tablets. 11

    2-1-3-2. Tablets used in the oral cavity. 16

    2-1-3-3. Tablets that are taken by other means than by mouth. 18

    2-1-3-4. Tablets used to prepare solutions. 19

    2-1-4. Rapid release tablets. 20

    2-1-4-1. Benefits of immediate release tablets. 20

    2-1-4-2. Disadvantages of immediate release tablets. 22

    2-1-4-3. Important points in the preparation of quick-release tablets. 22

    2-1-5. Rapid release tablet formulations. 24

    2-1-5-1. Effective ingredients in the formulation of quick-release tablets. 24

    2-1-5-2. Excipients in the formulation of quick-release tablets. 24

    2-1-5-2-1. Diluents.. 25

    2-1-5-2-2. Adhesives.. 26

    2-1-5-2-3. Lubricants.. 26

    2-1-5-2-4. Dyes.. 27

    2-1-5-2-5. Sweeteners. 27

    2-1-5-2-6. Flavorings.. 27

    2-1-5-2-7. Openers.. 28

    2-1-5-2-7-1. Types of openers. 28

    2-1-5-2-7-2. New openers. 29

    2-1-5-2-7-3. Effective factors in the opening of tablets. 30

    2-1-5-2-7-4. Mechanism of action of openers. 31

    2-1-6. Methods of producing quick release tablets. 40

    2-1-6-1. direct compression.. 40

    2-1-6-2. Dry granulation. 40

    2-1-6-3. Wet granulation. 41

    2-1-7. New technologies for making fast-release tablets. 42

    2-1-7-1. Zydis technology.. 42

    2-1-7-2. Orasolv technology. 43

    2-1-7-3. Durasolv technology. 44

    2-1-7-4. Wow tab technology. 45

    2-1-7-5. Flashdose technology. 46

    2-1-7-6. Flashtab technology. 46

    2-1-7-7. Oraquick technology. 46

    2-1-8. Physicochemical control tests of quick release tablets. 47

    2-1-8-1. The appearance of the tablet. 47

    2-1-8-2. Pharmaceutical form uniformity test. 48

    2-1-8-3. Weight uniformity test. 48

    2-1-8-4. Content uniformity test. 48

    2-1-8-5. Difficulty.. 49

    2-1-8-6. Erodibility test. 50

    2-1-8-7. Open time test. 50

    2-1-8-8. Test to determine the amount of active pharmaceutical ingredient. 50

    2-1-8-9. Stability test.. 51

    Second part: Amlodipine

    2-2-1. Mechanism of action.. 53

    2-2-2. Drug metabolism and pharmacokinetics. 54

    2-2-3. Cases and amount of consumption.. 54

    2-2-4. Precautions in use. 55

    2-2-5. Contraindications.. 55

    2-2-6. Side effects.. 55

    2-2-7. Drug interactions.. 55

    2-2-8. Recommendations.. 55

    Chapter Three: Materials and Methods

    3-1. Devices used.. 57

    3-2. Materials used.. 58

    3-3. Characteristics of some ingredients in the formulation. 59

    3-3-1. Sodium croscarmellose.. 59

    3-3-2. Cross povidone.. 60

    3-3-3. Sodium starch glycolate. 61

    3-3-4. Magnesium stearate.. 62

    3-3-5. Mannitol.. 62

    3-3-6. Microcrystalline cellulose.. 64

    3-3-7. sodium saccharin.. 64

    3-3-8. Aspartame.. 65

    3-3-9. Sodium lauryl sulfate.. 66

    3-3-10. Talc.. 66

    3-3-11. F-Melt.. 67

    3-4. Done works.. 67

    3-4-1. Preformulation studies performed on amlodipine powder. 67

    3-4-1-1. Examining the organoleptic properties of amlodipine powder. 68

    3-4-1-2. Determination of amlodipine powder drop. 68

    3-4-1-3. Investigating the compressibility of amlodipine powder. 69

    3-4-1-4. Determination of the UV spectrum of amlodipine. 69

    3-4-1-5. FTIR spectrum drawing of amlodipine. 69

    3-5. Preparation of fast-release oral tablet formulations of amlodipine. 70

    3-5-1. Method and preparation of fast-opening oral tablet formulations of amlodipine by direct compression method 70

    3-5-1-1. Preparation of fast-opening tablet formulationsPreparation of fast-opening tablet formulations of Amlodipine-Series A. 70

    3-5-1-2. Preparation of quick-release tablet formulations of amlodipine-series B. 71

    3-5-1-3. Preparation of quick-release tablet formulations of amlodipine-series C. 72

    3-6. Physicochemical control tests performed on fast-dissolving tablet formulations. 73

    3-6-1. Examining the appearance properties of tablets. 73

    3-6-2. Examining the hardness of tablets. 73

    3-6-3. Examining the erodibility of tablets. 73

    3-6-4. Determination of thickness and diameter of tablets. 74

    3-6-5. Checking the uniformity of the weight of tablets. 74

    3-6-6. Tablet opening time tests. 74

    3-6-7. Standard graph of amlodipine at 239 nm in HClo.1N medium. 74

    3-6-8. Determination of the amount of amlodipine. 75

    3-6-9. Dissolution test and drug release method. 75

    3-6-10. Taste test on superior formulation. 76

    Chapter Four: Results

    4-1. The results of pre-formulation studies conducted on amlodipine powder. 79

    4-1-1. The results of examining the organoleptic characteristics of amlodipine powder. 79

    4-1-2. Results related to the determination of amlodipine powder spillage. 79

    4-1-3. The results related to the compressibility of amlodipine powder. 81

    4-1-4. The results related to the UV spectrum of amlodipine powder in 0.1 NHCl environment. 82

    4-1-5. Results related to FTIR spectrum of amlodipine powder. 83

    4-1-6. Results related to determining the amount of amlodipine tablets. 84

    4-1-7. General conclusion of the studies conducted on amlodipine powder. 85

    4-2. Results related to formulations and physicochemical control of amlodipine fast-release tablets. 85

    4-2-1. The results of the physicochemical control tests on Amlodipine formulations - Series A 86

    4-2-2. The results of physicochemical control tests on amlodipine formulations - B series 86

    4-2-3. The results of physicochemical control tests on amlodipine formulations - C 87 series

    4-2-4. The results of the taste test on the selected formulation (D series formulations). 88

    4-3. Results from the dissolution of superior formulations. 89

    Chapter Five: Discussion and Conclusion

    5-1. Discussion and conclusions related to formulations and physicochemical control of quick-release tablets of amlodipine by direct compression method. 93

    5-2. General conclusion regarding better formulation by direct compression method. 94

    5-3. Study of sweetener in quick-opening tablets of amlodipine by direct compression method. 94

     

    English abstract. 95

    Resources

    Source:

     

     

    1) Collette D.M. Pharmaceutical preparations. In: Collete D.M., Aulton MG. Pharmaceutical practice. Edinburgh: Living stone; 1990. p. 145-156.

    2) Katzung, Bertram. Basic and clinical pharmacology. Translated by Mehrnaz Razvanfard. Tehran: Andisheh Rafi; 2019. Volume I. pp. 231,232.

    3) Katzung, Bertram. Basic and clinical pharmacology. Translated by Mehrnaz Razvanfard. Tehran: Andisheh Rafi; 2019. Volume I. p. 211. 4 (Bazsafid, Sara "Formulation and Physicochemical Control of Ibuprofen Effervescent Tablets" Ph.D. Dissertation of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran: p. 84, 80, 74, 72.

    5) Guad RS, Gupta D. Practical pharmaceutics ed. India: CBS publications and distributions 2002 p. 242-249.

    6) Ketani, Saba "Formulation of carbamazepine 100 mg fast-release oral tablet and investigation of its physicochemical properties" PhD Thesis of Pharmacy, Islamic Azad University, Department of Pharmaceutical Sciences, Tehran; 1389-1990 pp. 59-9.

    7) Ansel H.C. Oral solids and tablets. In: Ansel H.C. Pharmaceutical dosage forms and drug delivery systems. The ed. Philadel-phia: loppincot willicus and wilknis: 2000.p.164-228.

    8) Collete D.M. Pharmaceutical preparations. In collete D.M., Aulton MG. Pharmaceutical practice. Edinburgh: Living stone; 1990. p.145-156.

    9) Benker G.S, Peck G.E. Tablet formulation and design in: Liberman H.A and lechman L. Pharmacopeia Dosage form: tablets. ed. New York: Marcel Dekker; 1990. p. 369-417.

    10) Narin J.G. Solution emulsion suspensions and extracts. In Gennaro A.R. Remington the science and practice of pharmacy. 20th ed. Pennsylvania: Mack publishing company; 2000.p.721-752.

Formulation of fast-opening oral tablet of amlodipine 5 mg and investigation of its physicochemical properties